• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Expert Opinion on Pharmacotherapy

    Expert Opinion on Pharmacotherapy

    JournalISSN 1465-6566eISSN 1744-7666中科院 医学 4区

    年发文量

    研究主题

    论文(6511)

    排序
    1Structural Brain Abnormality, Pharmacotherapy, and Treatment Resistant Schizophrenia Management: a Systematic Review and Critical Appraisal.
    Andrea de Bartolomeis,Licia Vellucci,Federica Iannotta,Annarita Barone,Marta Matrone,Mariateresa Ciccarelli
    2026
    引用
    AI阅读
    加入学术空间
    2Pharmacotherapeutic Strategies for the Treatment of the Most Frequent Psychiatric Comorbidities in PTSD.
    Marina Sagud,Špiro Janovic, Domagoj Vidovic,Nenad Jaksic,Nela Pivac

    INTRODUCTION Posttraumatic stress disorder (PTSD) is trauma- and stressor-related disorder frequently associated with somatic and psychiatric comorbidities. The most frequent psychiatric comorbidities are major depressive disorder (MDD), sleep disturbances, alcohol use disorders (AUD) and psychoses. The lack of clinical improvement is frequent in PTSD, and presence of comorbidities complicates PTSD treatment. AREAS COVERED This narrative review covered pharmacotherapy of common psychiatric comorbidities in PTSD (MDD, psychosis, sleep disturbances, especially obstructive sleep apnea (OSA) and insomnia and AUD. We searched for novel data in reviews, randomized clinical trials, open labeled studies in English language through June 2026, identified using PubMed/MEDLINE/Web of Sciences/Google Scholar and clinical practice guidelines from the American Psychological Association for the Treatment of PTSD in adults (2025), and the US Department of Veterans Affairs and Department of Defense from 2023. We discussed available evidence related to pharmacotherapy of PTSD with comorbidities. EXPERT OPINION The vast majority of PTSD patients have at least one psychiatric comorbidity. Pharmacological treatment represents a challenge, given that pharmacological agents used to treat PTSD mostly do not affect symptoms of other comorbid disorders. Therefore, the choice of medications is highly individual, depending on the clinical presentation, tolerability issues, physical comorbidities, and patient preference.

    2026
    引用
    AI阅读
    加入学术空间
    3Contemporary Pharmacotherapy for Familial Hypercholesterolemia in Children and Adolescents.
    Fabiana C. Juliani, Kartagena M. Borges, Bruna B. Henares, Cecília S. Alvo,Raul D. Santos,Viviane Z. Rocha
    2026
    引用
    AI阅读
    加入学术空间
    4Will Sarcopenia Preventative Pharmacology Ensure the Long-Term Success of GLP-1-derived Therapies?
    Cauã Teixeira Mota, Alef Mendes Aguiar,Guilherme Wesley Peixoto da Fonseca
    2026
    引用
    AI阅读
    加入学术空间
    5Pharmacological Management of Moderate-to-severe Plaque Psoriasis in Patients with Cancer
    Matteo Megna,Michela D’Agostino,Nello Tommasino,Davide Fattore,Maria Esposito,Luca Potestio
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 6511 篇论文

    高被引作者

    作者引用发文
    Dimitri P. Mikhailidis111540
    Sheila A. Doggrell92992
    William J Gradishar7221
    Joseph H Friedman6756
    Shyam Sundar6432
    Jaya Chakravarty6432
    Murali Chakinala6371
    Simone Ferrero63116
    Kaiser Peter K6292
    Jo Nijs6293

    高产作者

    作者引用发文
    Sheila A. Doggrell92992
    Dimitri P. Mikhailidis111540
    Gregory YH Lip23332
    Antoniu Sabina Antonela25128
    Mario Cazzola38928
    Paola Rogliani26227
    Maria Gabriella Matera35826
    Steven R. Feldman56326
    Constantin A. Dasanu14822
    Nikolaos Papanas49422

    相关期刊

    British Journal Of Clinical Pharmacology
    Advances in therapy
    Current medical research and opinion
    European Journal of Clinical Pharmacology
    Expert opinion on investigational drugs
    Expert opinion on drug safety
    Clinical drug investigation
    Expert review of clinical pharmacology
    Drugs
    Clinical Therapeutics